Access count of this item: 223

Files in This Item:
File Description SizeFormat 
43_849.pdf460.83 kBAdobe PDFView/Open
Title: 前立腺癌患者における骨代謝,燐代謝の検討 : パラクライン的影響とエンドクライン的影響について
Other Titles: Bone metabolism and phosphorus metabolism in patients with prostate cancer: paracrine and endocrine effects produced by prostate neoplasm
Authors: 佐谷, 博之  KAKEN_name
山川, 謙輔  KAKEN_name
川村, 壽一  KAKEN_name
森, 脩  KAKEN_name
斉藤, 薫  KAKEN_name
加藤, 廣海  KAKEN_name
栃木, 宏水  KAKEN_name
桜井, 正樹  KAKEN_name
加藤, 貴裕  KAKEN_name
Author's alias: SATANI, Hiroyuki
MORI, Osamu
SAITO, Kaoru
KATO, Hiromi
KATO, Takahiro
Keywords: Prostate cancer
Bone metabolism
Phosphorus metabolism
Issue Date: Dec-1997
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 43
Issue: 12
Start page: 849
End page: 854
Abstract: We examined whether paracrine factors produced by prostate cancer cells can modulate bone metabolism in proportion to the volume of cancer cells in bone metastasis. Endocrine factors produced by prostate cancer cells affect both phosphate and 1, 25-dihydroxyvitamin D metabolisms. Levels of urine pyridinoline (U-Pyr) excretion and serum carboxy-terminal propeptide of type 1 procollagen (P1CP) in patients with bone metastasis were significantly higher than those in patients without bone metastasis (P< 0.05). In patients with bone metastasis (n= 1 7), serum prostate-specific antigen (PSA) levels were significantly correlated with the levels of U-Pyr and urine deoxypyridinoline (U-dPyr) excretion, serum cross-linked carboxyterminal telopeptide of type 1 collagen (1CTP), and P1CP levels (p < 0.05). However, serum PSA levels were not correlated with U-Pyr, U-dPyr excretions, serum ICTP and P1CP levels in patients without bone metastasis. Therefore, prostate cancer cells appear to have some paracrine effects on bone cells. In controls (n=15), serum 1, 25dihydroxyvitamin D levels (1, 25-(OH)2D) were inversely correlated with serum phosphorus levels (P<0.01). In prostate cancer patients with bone metastasis, the ability to regulate the serum 1, 25(OH)2D levels in response to serum phosphorus levels is lost. These results suggest that endocrine factors produced by prostate cancer cells disturb the regulation of serum 1, 25-(OH)2D in response to serum phosphorus levels. (Acta Urol. Jpn. 43: 849-854, 1997)
PubMed ID: 9488931
Appears in Collections:Vol.43 No.12

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.